Practice points - Neonatal Intensive Care Drug Manual

|
Neonatal Intensive Care Drug Manual
|
bet | 72/654 | Sana | 03.01.2022 | Hajmi | 1,5 Mb. | | #14803 |
Practice points
|
|
References
|
Micromedex solutions. Amphotericin B. Accessed on 29 April 2017.
Tripathi N, Watt K, Benjamin Jr DK. Treatment and prophylaxis of invasive candidiasis. Semin Perinatol 2012;36:416-23
MIMS Online accessed on 15 June 2017.
van den Anker JN, van People NML, Sauer PJJ. Antifungal agents in neonatal systemic Candidiasis. Antimicrob Agents Chemother 1995;39:1391-7
Australian Injectable Drugs Handbook, 6th Edition
Chen SC, Sorrell TC, Chang CC, Paige EK, Bryant PA, Slavin MA. Consensus guidelines for the treatment of yeast infections in the haematology, oncology and intensive care setting, 2014. Intern Med J 2014;44:1315-32
Juster-Reicher A, Flidel-Rimon O, Amitay M, Even-Tov S, Shinwell E, Leibovitz E. High-dose liposomal amphotericin B in the therapy of systemic candidiasis in neonates. Eur J Clin Microbiol Infect Dis 2003;22:603-7
Wurthwein G, Groll AH, Hempel G, Adler-Shohet FC, Lieberman JM, Walsh TJ. Population pharmacokinetics of amphotericin B lipid complex in neonates. Antimicrob Agents Chemother 2005;49:5092-8
Nau R, Sörgel F, Eiffert H. Penetration of Drugs through the Blood-Cerebrospinal Fluid/Blood-Brain Barrier for Treatment of Central Nervous System Infections. Clinical Microbiology Reviews. 2010;23(4):858-83.
Clerihew L, McGuire W. Antifungal therapy for newborn infants with invasive fungal infection. Cochrane Database Syst Rev. 2012 Jun 13;(6):CD003953 doi: 10.1002/14651858.CD003953.pub3
Blyth CC, Hale K, Palasanthiran P, O’Brien T, Bennett MH. Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections. Cochrane Database Syst Rev. 2010, Feb 17;(2):CD006343. doi: 10.1002/14651858.CD006343 pub2
Driessen M, Ellis JB, Cooper PA, Wainer S, Muwazi F, Hahn D et al. Fluconazole vs amphotericin B for the treatment of neonatal fungal septicaemia: a prospective randomized trial. Pediatr Infect Dis J 1996;15:1107-12
Weitkamp JH, Poets CF, Sievers R, Musswessels E, Groneck P, Thomas P et al. Candida infection in very low birth-weight infants: Outcome and nephrotoxicity of treatment with liposomal amphotericin B (AmBisome). Infection 1998;26:11-5.
Juster-Reicher A, Leibovitz E, Linder N, Amitay M, Flidel-Rimon O, Even-Tov S et al. Liposomal amphotericin B (AmBisome) in the treatment of neonatal candidiasis in very low birth weight infants. Infection 2000;28:223-6
Botero Aguirre JP, Restrepo Hamid AM. Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney function. Cochrane Database Syst Rev 2015 Nov 23;(11):CD010481.
Ascher SB, Smith PB, Watt K et al. Antifungal therapy and outcomes in infants with invasive candida infections. Pediatr Infect Dis J 2012;31:439-43
Clark E, Giambra BK, Hingl J et al. Reducing risk of harm from extravasation: a 3-tiered evidence-based list of pediatric peripheral intravenous infusates. J Infus Nurse 2013;36:37-45
Roberts JK, Stockmann C, Constance JE et al. Pharmacokinetics and pharmacodynamics of antibacterials, antifungals, and antivirals used most frequently in neonates and infants. Clin Pharmacokinet 2014;53:581-610.
Cota JM, Burgess DS. Antifungal dose adjustment in renal and hepatic dysfunction: Pharmacokinetic and pharmacodynamics considerations. Curr Fungal Infect Rep 2010;4:120-8.
|
Original version Date: 17/07/2017
|
Author: ANMF Consensus Group
|
Current Version number: 3
|
Version Date: 16/11/2020
|
Risk Rating: Low
|
Due for Review: 16/11/2025
|
Approval by: DTC
|
Approval Date: TBA
|
|
| |